EICHORPublic-registry site landscape for NCT07698587, “A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors”, a Solid Tumor study sponsored by Suzhou Biomissile Pharmaceuticals Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07698587 (registry record) |
| Study title | A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors |
| Official title | A Phase Ib/II, Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Combination With PD-1 Inhibitor in Patients With HER2-Related Advanced Solid Tumors |
| Sponsor | Suzhou Biomissile Pharmaceuticals Co., Ltd. |
| Condition(s) | Solid Tumor |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 1 |
| Site countries | China |
At First Affiliated Hospital of Anhui Medical University — one of the facilities listed on this trial — 46 other studies are actively recruiting Solid Tumor patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07698587.
Eichor generates a preliminary site-risk snapshot for NCT07698587 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Solid Tumor trials
← Eichor home · All tracked trials · Solid Tumor studies · Weekly briefs
